Role of Vitamin D in Infliximab-induced Remission in Adult Patients with Crohn's Disease

Inflammatory Bowel Diseases

Volumn 22, Issue 1, 2016, Pages 92-99

  Reich, Krista M ^a   Fedorak, Richard N ^a   Madsen, Karen ^a   Kroeker, Karen I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Crohn's disease; cytokines; HRQoL; infliximab; remission; Vitamin D

Indexed keywords

COLECALCIFEROL; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; VITAMIN D; CYTOKINE; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; CYTOKINE RELEASE; FEMALE; HUMAN; MALE; MIDDLE AGED; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; CHEMICALLY INDUCED; COMPLICATION; FOLLOW UP; METABOLISM; PROGNOSIS; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; CROHN DISEASE; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 84964578138     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000588     Document Type: Article

References (42)

1. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329-342.
2. Altwegg R, Vincent T. TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. Mediators Inflamm. 2014;2014: 172821.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomized trial. Lancet. 2002;359: 1541-1549.
4. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
6. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's Disease: The CLASSIC-I Trial. Gastroenterology. 2006;130:323-333.
7. Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol. 2014;20:3146-3152.
8. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430-1438.
9. Hewison M. Vitamin D and immune function: an overview. Proc Nutr Soc. 2011;71:50-61.
10. Reich KM, Fedorak RN, Madsen K, et al. Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review. World J Gastroenterol. 2014;20:4934-4947.
11. Suibhne TN, Cox G, Healy M, et al. Vitamin D deficiency in Crohn's disease: prevalence, risk factors and supplement use in an outpatient setting. J Crohns Colitis. 2012;6:182-188.
12. Khalili H, Haung E, Ananthakrishnan A, et al. Geographical variation and incidence of inflammatory bowel disease among US women. Gut. 2012; 61:1686-1692.
13. Stio M, Treves C, Martinesi M, et al. Biochemical effects of KH 1060 and anti-TNF monoclonal antibody on human peripheral blood mononuclear cells. Int Immunopharmacol. 2005;5:649-659.
14. Zhu Y, Mahon BD, Froicu M, et al. Calcium and 1alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35:217-224.
15. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease - A randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377-383.
16. Yang L, Weaver V, Smith JP, et al. Therapeutic effect of vitamin D supplementation in a pilot study of Crohn's patients. Clin Transl Gastroenterol. 2013;4:e33.
17. Zator Z, Cantu SM, Konijeti GG, et al. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-A therapy in inflammatory bowel diseases. JPEN J Parenter Enteral Nutr. 2014;38:385-391.
18. Diamond TH, Ho KW, Rohl PG, et al. Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Med J Aust. 2005;183:10-12.
19. Tellioglu A, Basaran S, Gruzel R, et al. Efficacy and safety of high dose intramuscular or oral cholecalciferol in vitamin D deficient/insufficient elderly. Maturitas. 2012;72:332-338.
20. Zabihiyeganeh M, Jahed A, Nojomi M. Treatment of hypovitaminosis D with pharmacologic doses of cholecalciferol, oral vs intramuscular; an open labeled RCT. Clin Endocrinol (Oxf). 2013;78:210-216.
21. de Jager W, Bourcier K, Rijkers GT, et al. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol. 2009;10:52.
22. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
23. Rutgeerts P. Review article: efficacy of infliximab in Crohn's disease- induction and maintenance of remission. Aliment Pahrmacol Ther. 1999; 13:9-15.
24. Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis. 2013;19:1921-1927.
25. Costa J, Magro F, Caldeira D, et al. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: A systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19:2098-2110.
26. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
27. van Deventer SJH. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology. 2001;121:1242-1246.
28. Bartels LE, Jorgensen SP, Bendix M, et al. 25-Hydroxy vitamin D3 modulates dendritic cell phenotype and function in Crohn's disease. Inflammopharmacology. 2013;21:177-186.
29. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211.
30. Aversa G, Punnonen J, de Vries JE. The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation. J Exp Med. 1993; 177:1575-1585.
31. Khoo AL, Chai LY, Koenen HJ, et al. Regulation of cytokine responses by seasonality of vitamin D status in healthy individuals. Clin Exp Immunol. 2011;164:72-79.
32. Atreya R, Zimmer M, Bartsch B, et al. Antibodies against tumor necrosis factor (TNF) induced T cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages. Gastroenterology. 2011;141:2026-2038.
33. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
34. Harada A, Sekido N, Akahoshi T, et al. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol. 1994;56:559-564.
35. Marks D, Harbord M, MacAllister R, et al. Defective acute inflammation in Crohn's disease: A clinical investigation. Lancet. 2006;367:668-678.
36. Somasundaram R, Nuij V, van der Woude C, et al. Peripheral neutrophil functions and cell signaling in Crohn's disease. PLoS One. 2013;8:e84521.
37. Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis. 2002;8:237-243.
38. Wright JP, Marks IN, Parfitt A. A simple clinical index of Crohn's disease activity-The Cape Town index. S Afr Med J. 1985;68:502-503.
39. af Björkesten CG, Nieminen U, Turunen U, et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol. 2012;47:528-537.
40. Teshima CW, Thompson A, Dhanoa L, et al. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol. 2009;23:348-352.
41. Jelsness-Jørgensen L-P, Bernklev T, Moum B. Calprotectin is a useful tool in distinguishing coexisting irritable bowel-like symptoms from that of occult inflammation among inflammatory bowel disease patients in remission. Gastroenterol Res Pract. 2013;2013:620707.
42. Alpert PT, Shaikh U. The effects of vitamin D deficiency and insufficiency on the endocrine and paracrine systems. Bio Res Nurs. 2007;9:117-129.